13th Meeting, short summary report, June 2024, Lyon, France

Overview

Meetings of the WHO-AVWG are convened annually by WHO collaborating centres (WHO CCs), representative National influenza centres (NICs), and WHO H5 reference laboratories to review the susceptibility of global seasonal and emerging influenza viruses to approved antivirals, including neuraminidase (NA) inhibitors (NAIs) and the cap-dependant endonuclease inhibitor (CENI) baloxavir marboxil (baloxavir). The overall objective of the WHO-AVWG meeting is to provide practical guidance to the NICs of GISRS for surveillance of antiviral susceptibility. The 13th WHO-AVWG meeting was held in hybrid format (face-to-face and virtually) on 13-14 June 2024 in Lyon, France.